Search

REVOLUTION Medicines Inc

Fechado

SetorSaúde

203.4 -0.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

199.66

Máximo

206.37

Indicadores-chave

By Trading Economics

Rendimento

-644M

-1.1B

EPS

-2.34

Funcionários

883

EBITDA

-184M

-621M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+23.69% upside

Dividendos

By Acuity

Próximos Ganhos

4 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

6.2B

45B

Abertura anterior

204.34

Fecho anterior

203.4

Sentimento de Notícias

By Acuity

76%

24%

308 / 339 Ranking em Healthcare

REVOLUTION Medicines Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de set. de 2026, 20:08 UTC

Revolution Medicines Inc shares are higher during Friday's session, despite earlier pulling back from an intraday high. No specific news was identified for the movement.

3 de set. de 2026, 19:16 UTC

News

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2 de set. de 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

1 de set. de 2026, 23:06 UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

31 de ago. de 2026, 20:07 UTC

Correlated Moves
News

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

28 de ago. de 2026, 20:02 UTC

Social Media
News

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

27 de ago. de 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

26 de ago. de 2026, 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

25 de ago. de 2026, 20:07 UTC

News

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

24 de ago. de 2026, 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 de ago. de 2026, 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 de ago. de 2026, 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 de ago. de 2026, 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 de ago. de 2026, 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 de ago. de 2026, 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 de ago. de 2026, 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 de ago. de 2026, 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 de ago. de 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 de ago. de 2026, 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 de ago. de 2026, 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 de ago. de 2026, 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 de ago. de 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 de ago. de 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 de jul. de 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 de jul. de 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 de jul. de 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 de jul. de 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 de jul. de 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 de jul. de 2026, 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 de jul. de 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

Comparação entre Pares

Variação de preço

REVOLUTION Medicines Inc Previsão

Preço-alvo

By TipRanks

23.69% parte superior

Previsão para 12 meses

Média 252.053 USD  23.69%

Máximo 320 USD

Mínimo 179 USD

Com base em 21 analistas de Wall Street que oferecem metas de preço de 12 meses para REVOLUTION Medicines Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

21 ratings

20

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

308 / 339 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat